艾昆纬-MASH临床研究见解-GLP-1激动剂的可及性增加（英）-2024
Insights into MASH Enrollment amid increasing access to GLP-1 agonists TRACY HARDY, Senior Director, Head of Therapeutic Strategy and Innovation, Gastroenterology Center of Excellence
报告摘要
Insights into MASH Enrollment amid increasing access to GLP-1 agonists TRACY HARDY, Senior Director, Head of Therapeutic Strategy and Innovation, Gastroenterology Center of Excellence
报告信息
- 文件全名
- 《艾昆纬-MASH临床研究见解-GLP-1激动剂的可及性增加（英）-2024-13页.pdf》
- 适合读者
- 核心数据
- in MASH faces challenges, with an 83% decrease in
- trials. Unit sales of GLP-1s increased in the U.S. by 1,265%
- 核心议题
常见问题
《艾昆纬-MASH临床研究见解-GLP-1激动剂的可及性增加（英）-2024》主要包含哪些内容?
Insights into MASH Enrollment amid increasing access to GLP-1 agonists TRACY HARDY, Senior Director, Head of Therapeutic Strategy and Innovation, Gastroenterology Center of Excellence核心数据:in MASH faces challenges, with an 83% decrease in;trials. Unit sales of GLP-1s increased in the U.S. by 1,265%。
这份报告由哪家机构发布?
本报告由艾昆纬发布,发布于 2024 年。
这份报告覆盖哪一年、篇幅多大?
覆盖 2024 年,全文约 13。
这份报告是免费的吗?如何获取?
本报告免费查阅,登录资料宝后即可在线获取完整内容。
这份报告适合哪些读者?
适合战略规划、行业研究员等读者参考。
报告涉及哪些关键议题?
重点分析了管理咨询等议题。
继续阅读
查看全部 →